Zydus Cadila receives final approval from USFDA for Deferasirox Tablets for Oral Suspension

Myequity news | Date : 07-05-2020 17:15:00 IST

Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets for Oral Suspension (US RLD: ExjadeTM Tablets for Oral Suspension) in the strengths of 125 mg, 250 mg and 500 mg.

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in
adults and children who are at least 10 years old.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 289 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and lood is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

More from Myequity